Skip to main content

Table 3 Pharyngeal arch artery defects in mutant E10.5 embryos

From: Msx1 haploinsufficiency modifies the Pax9-deficient cardiovascular phenotype

Genetic background

n

PAA

Abnormal

Unilateral

Bilateral

Bilateral defects

Present

Hypo/Int/Abs

Absent

B6-Pax9–/– a

20

1

11 (55%)

1

10

9

1

0

2

8 (40%)

3

5

4

1

0

3

15 (75%)

3

12

–

8

4

4

20 (100%)

1

19

–

3

16

CD1-Pax9–/–

9

1

7 (78%)

1

6

6

0

0

2

8 (89%) *

1

7

7

0

0

3

8 (89%)

0

8

–

3

5

4

9 (100%)

0

9

–

0

9

CD1-Pax9–/–;Msx1+/–

16

1

8 (50%)

0

8

8

0

0

2

8 (50%)

0

8

8

0

0

3

4 (25%) **

0

4

–

3

1

4

16 (100%)

0

16

–

6*

10

  1. Embryos were collected at E10.5 and assessed for pharyngeal arch artery (PAA) defects by intracardiac ink injection
  2. **p < 0.005, *p < 0.05 (Fisher’s exact test for associations)
  3. aData for Pax9–/– embryos on a C57Bl/6J (B6) genetic background have been published [3]. For Pax9–/– embryos, each left and right PAA 1–4 was scored as having a unilateral or bilateral defect, and the bilateral defects categorised as either present, a combination of hypoplastic, interrupted and/or absent (Hypo/Int/Abs), and bilaterally absent. All control B6-Pax9+/+ (n = 18) and CD1-Pax9+/+ (n = 12) embryos were normal. CD1-Pax9+/+;Msx1–/– (n = 6) and CD1-Pax9+/–;Msx1–/– (n = 7) embryos were normal. The increase in abnormal 2nd PAAs in CD1-Pax9–/– compared with B6-Pax9–/– embryos is significant. The decrease in 3rd PAA defects, and the increase in hypoplastic 4th PAA defects, in CD1-Pax9–/–;Msx1+/– compared with CD1-Pax9–/– embryos is significant